| Join Xconomy Next Week at the Virtual Xcelerate Keynote Series at Biotech Week Boston | Editors | 09/14/20 | Boston |
| Bio Roundup: COVID-19 Pact, Gavreto Approval, Generative Biology & More | Frank Vinluan | 09/11/20 | National |
| Now Closer to Clinical Trials, Codiak BioSciences Refiles IPO Plans | Frank Vinluan | 09/10/20 | Boston |
| Generate Bio Aims to Reveal Nature’s Protein Secrets, Create New Drugs | Frank Vinluan | 09/10/20 | Boston |
| Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue | Frank Vinluan | 09/09/20 | National |
| Grifols Moves Deeper Into Proteome R&D With $146M Deal for Alkahest | Frank Vinluan | 09/08/20 | San Francisco |
| FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures | Frank Vinluan | 09/05/20 | Boston |
| Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More | Frank Vinluan | 09/04/20 | National |
| Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally | Frank Vinluan | 09/03/20 | Boston |
| Lumen Bioscience Lands $16M to Engineer “Edible” Antibody Drugs | Frank Vinluan | 09/02/20 | Seattle |
| Gilead Sciences Places $120M Bet on a Jounce Therapeutics Cancer Drug | Frank Vinluan | 09/01/20 | San Francisco |
| Early Bird Sale for Xcelerate at Biotech Week Boston Ends This Friday | Editors | 08/31/20 | Boston |
| Akcea Therapeutics Is Returning to Parent Ionis Pharma in $500M Buyout | Frank Vinluan | 08/31/20 | Boston |
| Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More | Frank Vinluan | 08/28/20 | National |
| Freenome Tacks on $270M to Advance Blood Tests to Find Cancer Early | Sarah de Crescenzo | 08/26/20 | San Francisco |
| Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases | Frank Vinluan | 08/26/20 | Boston |
| FDA Adds Plasma as 2nd COVID-19 Treatment Under Emergency Guidelines | Sarah de Crescenzo | 08/24/20 | National |
| Yumanity to Merge With Proteostasis to Advance Neuro Drug Pipeline | Frank Vinluan | 08/24/20 | Boston |
| Astellas Reports Third Patient Death in Audentes Gene Therapy Study | Frank Vinluan | 08/21/20 | San Francisco |
| Bio Roundup: J&J Buyout, BioMarin Rebuffed, Poseida on Hold & More | Sarah de Crescenzo | 08/21/20 | National |
| Alzheon Lands $47M to Take Another Shot at a Pivotal Alzheimer’s Test | Frank Vinluan | 08/20/20 | Boston |
| J&J Boosts Autoimmune Disease Drug Pipeline With $6.5B Momenta Buyout | Frank Vinluan | 08/19/20 | New York |
| Genentech Gets FDA OK for Injectable Rare Neuroimmune Disease Drug | Sarah de Crescenzo | 08/18/20 | San Francisco |
| Tango Therapeutics Adds $175M, Deal Turns Partner Gilead Into Investor | Sarah de Crescenzo | 08/17/20 | Boston |
| Bristol Myers Squibb to Splash Out $475M on Dragonfly Immunotherapy | Sarah de Crescenzo | 08/17/20 | New York |
| Bio Roundup: Seres Soars, MesoBlast Vote, Duchenne Decision & More | Frank Vinluan | 08/14/20 | National |
| With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor | Frank Vinluan | 08/12/20 | New York |
| Seres Sets Sights on FDA After C. Diff Microbiome Therapy Scores in Phase 3 | Frank Vinluan | 08/10/20 | Boston |
| AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact | Frank Vinluan | 08/07/20 | Boston |
| Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More | Sarah de Crescenzo | 08/07/20 | National |
